Small-Vessel Disease: When the Problem Is in Arteries the Angiogram Cannot Resolve

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL

The coronary arteries visible on an angiogram are the large epicardial vessels, the plumbing cardiology has imaged and stented for decades. Beyond them lies the coronary microvasculature, a network of small arterioles too fine to resolve on standard angiography, and the regulator of most coronary blood flow. When that network fails to dilate properly, the result is ischemia with no blockage to point to. This is coronary microvascular dysfunction, and it is a leading mechanism of ischemic symptoms in women.

The pathophysiology

Coronary blood flow is governed less by the large vessels than by the resistance arterioles, which dilate to match supply to demand. 4 / Promising In microvascular dysfunction, that dilatory capacity is impaired, through endothelial dysfunction, smooth-muscle dysfunction, or structural microvascular remodeling, so the heart cannot increase flow when it needs to. The angiogram, which images only the large vessels, is normal. The ischemia is real.

The condition tracks with the same factors that injure the endothelium broadly, and women carry several of them disproportionately, including the inflammatory and hormonal shifts addressed elsewhere in this series.

How it is diagnosed

Microvascular dysfunction is diagnosed by measuring coronary function, not anatomy. 4 / Promising Invasive coronary function testing quantifies coronary flow reserve, the ratio of maximal to resting flow, and microvascular resistance, distinguishing a microvascular endotype from a vasospastic one. The COVADIS criteria formalize the diagnosis of microvascular angina. Non-invasive approaches, including stress perfusion cardiac MRI and PET-derived flow reserve, can also assess microvascular function.

The CorMicA trial demonstrated that obtaining this functional information changes outcomes: stratifying therapy by the measured endotype improved angina and quality of life versus usual care (Ford et al, JACC 2018). 4 / Promising Diagnosis here is not academic labeling; it directs treatment.

Treatment by endotype

Management follows the mechanism. 3 / Early Microvascular angina is treated with agents aimed at improving microvascular function and controlling symptoms and risk factors, while a vasospastic component is treated differently, with emphasis on agents that counter spasm. The evidence base for specific regimens continues to develop, which is why this carries an early rating, but the principle, treat the endotype the testing reveals, is well supported. Aggressive risk-factor management underpins all of it.

What this means

Coronary microvascular dysfunction is disease in vessels the angiogram cannot resolve, and it is one of the most common reasons a woman has real ischemic symptoms with clean large arteries. It is diagnosable through coronary function testing and treatable by endotype, and the main barrier is that the testing is skipped. Making functional assessment routine after a normal angiogram is how small-vessel disease stops being invisible and starts being managed.

The coronary flow reserve threshold: what the number means

Coronary flow reserve, or CFR, is the ratio of maximal hyperemic coronary blood flow to resting flow. In a healthy microvasculature, the small vessels dilate substantially in response to increased demand, so CFR is typically above 2.5 and often above 3.0. When CFR falls below 2.0, microvascular dysfunction is considered significant. The threshold most widely used in research and clinical practice is a CFR below 2.5, though some definitions use 2.0 as the cutoff for more severe impairment.

The WISE program provided the prognostic data that made this threshold clinically meaningful. Women with CFR below 2.5 had substantially higher rates of major adverse cardiovascular events over follow-up compared with women with preserved CFR, and impaired CFR predicted outcomes independently of angiographic findings and traditional risk factors (Reis et al, NEJM 2001). 4 / Promising This was one of the first demonstrations that a functional measure, not an anatomic one, defined risk in women with non-obstructive disease.

The clinical implication is that a CFR below 2.5 is not a borderline finding to note and ignore. It identifies a patient with real ischemic physiology, elevated cardiovascular risk, and an indication for active management rather than reassurance. The number corresponds to a physiology: the heart cannot increase its blood supply in proportion to its demand, and the consequence is exertional or stress-induced ischemia that maps directly to the patient’s symptoms.

The index of microvascular resistance and how it differs from CFR

CFR measures the overall capacity of the coronary circulation to increase flow, which includes contributions from both the epicardial arteries and the microvascular bed. In a patient who also has epicardial disease, a reduced CFR may reflect epicardial stenosis rather than microvascular pathology. To isolate microvascular resistance specifically, invasive coronary function testing uses the index of microvascular resistance, or IMR.

IMR is calculated from pressure and temperature measurements made with a pressure-temperature wire during maximal hyperemia induced by adenosine. It measures resistance at the level of the microvasculature directly, independent of epicardial disease. An IMR above 25 is generally considered elevated, indicating microvascular dysfunction as distinct from epicardial limitation. 3 / Early

The distinction between CFR and IMR matters clinically. A patient with reduced CFR and normal IMR likely has epicardial flow limitation even if no obstructive stenosis is apparent. A patient with normal or mildly reduced CFR but elevated IMR has isolated microvascular resistance elevation. Each pattern implies a different mechanism and may respond differently to treatment. The CorMicA trial used both CFR and IMR, along with acetylcholine provocation testing for spasm, to assign endotype, which is why it could stratify treatment and show benefit: it was measuring the right things with sufficient granularity.

IMR has also been shown to predict outcomes after acute MI, where high IMR after revascularization identifies patients with microvascular injury who are at higher risk for adverse remodeling. In the INOCA population without prior MI, elevated IMR identifies microvascular dysfunction as the primary mechanism and helps direct the treatment choice.

Why women develop microvascular dysfunction more often: the biological reasons

The sex disparity in coronary microvascular dysfunction has several converging explanations, none of which is speculative.

Estrogen has direct effects on the coronary endothelium. It upregulates endothelial nitric oxide synthase, promoting nitric oxide production and vasodilation. It also has anti-inflammatory effects on the vessel wall and modulates the response to injury. As estrogen levels decline in perimenopause and menopause, these protective effects are lost. Studies using invasive coronary function testing have demonstrated measurable deterioration in microvascular function across the menopausal transition, with postmenopausal women showing lower CFR than premenopausal women matched for age and risk factors.

Inflammatory mediators play a separate and additive role. Women with microvascular dysfunction show elevated levels of inflammatory markers including C-reactive protein, interleukin-6, and tumor necrosis factor-alpha compared with women without the condition. These inflammatory signals injure the endothelium, impair nitric oxide signaling, and promote the structural remodeling of small vessels that underlies chronic microvascular dysfunction. Women are more likely than men to develop autoimmune and inflammatory conditions that drive systemic inflammation, and this biological tendency compounds the hormonal vulnerability.

Autonomic nervous system differences also contribute. Women have higher baseline sympathetic tone in the coronary microvasculature and may be more responsive to adrenergic stimulation, which promotes vasoconstriction. This heightened adrenergic responsiveness can translate into exaggerated vasomotor responses to stress, pain, or exertion that exceed what the microvasculature can accommodate.

Prevalence data from the WISE cohort and subsequent studies consistently show that among patients referred for evaluation of chest pain who have no obstructive coronary disease, women make up the large majority. In the CorMicA population, microvascular dysfunction and vasospasm accounted for the preponderance of diagnoses, and women were substantially over-represented in both endotypes compared with what atherosclerotic MI registries would predict.

Non-invasive imaging: cardiac PET and stress CMR

Not every patient with suspected microvascular dysfunction will undergo invasive coronary function testing. For some patients the question can be approached non-invasively, and two imaging modalities are most relevant.

Cardiac positron emission tomography, or PET, with a flow tracer such as rubidium-82 or nitrogen-13 ammonia can quantify absolute myocardial blood flow at rest and with pharmacologic stress. This allows calculation of myocardial flow reserve, the non-invasive analog of CFR. PET-derived flow reserve below 2.0 is associated with adverse cardiovascular outcomes and has been validated as a prognostic marker in large cohort studies. 4 / Promising PET provides spatial information as well, allowing identification of regional versus global impairment, which can help distinguish microvascular dysfunction from epicardial disease that was missed on angiography.

The limitation of PET is its availability. It requires a cyclotron on-site for nitrogen-13 or a rubidium generator, equipment not present at most community hospitals. Rubidium-82 PET is more widely available but still concentrated at academic and large referral centers. For a woman with suspected microvascular dysfunction in a community setting, PET may not be a realistic first-line option.

Stress perfusion cardiac MRI is an alternative with growing availability. CMR can detect subendocardial perfusion defects that represent microvascular ischemia, and studies have demonstrated its sensitivity for microvascular dysfunction in women with INOCA. The ISCHEMIA trial’s substudy work and subsequent CMR-specific analyses have provided normative data and outcome correlations. CMR also provides the simultaneous characterization of myocardial structure and function that is useful in the MINOCA workup described in the companion white paper.

The limitation of stress CMR is that protocol standardization varies between centers, and quantitative absolute flow measurement by CMR, which would most closely parallel PET, is technically demanding and not uniformly available. Most clinical stress CMR reports qualitative or semiquantitative perfusion assessments rather than absolute myocardial blood flow values.

Neither PET nor CMR fully replaces invasive coronary function testing when precise endotype characterization is the goal. The invasive approach distinguishes CFR from IMR from vasospasm in a single procedure and provides the granularity that the CorMicA trial showed changes management. Non-invasive imaging is a useful starting point for quantifying functional impairment, particularly when the clinical question is prognosis or when invasive testing is not feasible.

Treatment evidence: what the trials show for specific agents

The evidence base for pharmacologic treatment of microvascular angina is real but limited, and the limitations matter for clinical decision-making. 3 / Early

Ranolazine, a late sodium channel inhibitor, was tested in the RWISE trial, a randomized placebo-controlled trial in women with INOCA and signs of coronary microvascular dysfunction (Merz et al, JACC 2016). Ranolazine did not significantly improve myocardial perfusion reserve index on MRI compared with placebo, though it did improve angina symptoms in the subset with the most severe perfusion impairment. The result is humbling: it means that improving symptoms and improving the underlying physiology are not the same thing, and symptom response should not be taken as evidence that the mechanism is being corrected.

Beta-blockers reduce heart rate and myocardial oxygen demand and are frequently used in microvascular angina, particularly in patients with elevated resting heart rate or adrenergic-driven symptoms. The evidence for beta-blockers specifically in the microvascular angina population is largely observational rather than from dedicated randomized trials, but the physiological rationale is sound and they are recommended in management guidelines as first-line options in most endotypes.

ACE inhibitors and angiotensin receptor blockers reduce systemic vascular resistance, lower blood pressure, and have direct endothelial-protective effects. The WISE ancillary study data suggested that ACE inhibition in women with INOCA was associated with improved endothelial function as measured by noninvasive techniques. Risk factor control, including hypertension management, is the most consistent recommendation across all published management frameworks for microvascular dysfunction, not because it is exciting but because the endothelial injury that underlies most microvascular dysfunction is driven substantially by the same factors that drive systemic vascular disease.

Calcium channel blockers, particularly the non-dihydropyridine class, are the first-line pharmacologic treatment when vasospasm is the predominant endotype. For a patient with a mixed microvascular and vasospastic picture, which is common, a combination approach is typically used, though the evidence for specific combinations is thin.

Long-term cardiovascular risk of untreated microvascular dysfunction

The data on long-term outcomes for women with unmanaged microvascular dysfunction converge on a consistent finding: this is not a benign condition. 4 / Promising The WISE program five-year follow-up showed that women with impaired coronary flow reserve had annual event rates that, while lower than those seen in obstructive coronary disease, were substantially higher than expected for an apparently low-risk population with clean angiograms. The events included heart failure hospitalizations, non-fatal MI, stroke, and cardiovascular death.

More recent data from large registry analyses have confirmed this pattern. Women with INOCA who do not receive secondary prevention or endotype-directed treatment have repeat hospitalizations, ongoing symptom burden affecting quality of life and work capacity, and a meaningful rate of adverse cardiovascular events over five to ten years of follow-up. The lack of obstructive disease on angiography does not confer the low-risk trajectory that patients are often led to expect at discharge.

This outcome data is the strongest argument for systemic change in how non-obstructive ischemia is managed. When the prognosis with no treatment is adverse and the tools to measure and treat the condition exist, the decision to not measure and not treat is not conservative. It is the choice with the worse long-term outcome.

Questions to ask the cardiologist

After a normal angiogram with persistent symptoms, these questions delineate whether the evaluation has been adequate.

Has my coronary flow reserve been measured, either invasively or by PET imaging? If not, is there a reason, and what would the result change? Has anyone tested for coronary vasospasm with provocation testing? What is my diagnosis, specifically as a mechanism, not just “clear arteries”? What is my treatment and what endotype is it targeting? What is my cardiovascular risk over the next five to ten years based on current evidence, and what would change that trajectory? What symptoms should prompt me to return urgently, and what constitutes a red flag for this condition specifically?

A cardiologist who has evaluated coronary microvascular dysfunction appropriately will answer these questions without difficulty. If the answers are absent, the next step is referral to a center that performs invasive coronary function testing routinely and has experience in the COVADIS framework for microvascular and vasospastic endotype classification.